Blockade of IL-6 signal exacerbates acute inflammatory bowel disease via inhibiting IL-17 producing in activated CD4+ Th17 population

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 24, 2013, Pages 3291-3295

  Zhang, S J ^a   Wang, Lei ^a   Ming, L ^a   Guo, X B ^a   Wang, H M ^a   Li, X W ^a   Li, L ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

DSS; IL 6; Inflammatory bowel disease (IBD); Th17 cells

Indexed keywords

DOCUSATE SODIUM; INTERLEUKIN 17; INTERLEUKIN 6; NEUTRALIZING ANTIBODY;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELL POPULATION; CELL SURVIVAL; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; INFLAMMATORY BOWEL DISEASE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TH17 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; BIOLOGICAL MARKERS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-17; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MICE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TH17 CELLS; TIME FACTORS;

EID: 84891762735     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. MAYNARD CL, WEAVER CT. Intestinal effector T cells in health and disease. Immunity 2009; 31: 389-400.
2. STROBER W, FUSS IJ . Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1756-1767.
3. DUCHMANN R, KAISER I, HERMANN E, MAYET W, EWE K, MEYER ZUM BUSCHENFELDE KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-455.
4. CHENG X, YU X, DING YJ, FU QQ, XIE JJ, TANG TT, YAO R, CHEN Y, LIAO YH. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008; 127: 89-97.
5. FUJINO S, ANDOH A, BAMBA S, OGAWA A, HATA K, ARAKI Y, BAMBA T, FUJIYAMA Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
6. NIELSEN OH, KIRMAN I, RUDIGER N, HENDEL J, VAINER B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 180-185.
7. FINA D, SARRA M, FANTINI MC, RIZZO A, CARUSO R, CAPRIOLI F, STOLFI C, CARDOLINI I, DOTTORI M, BOIRIVANT M, PALLONE F, MACDONALD TT, MONTELEONE G. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134: 1038-1048.
8. MCGOVERN D, POWRIE F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 2007; 56: 1333-1336.
9. ZHOU L, IVANOV II, SPOLSKI R, MIN R, SHENDEROV K, EGAWA T, LEVY DE, LEONARD WJ, LITTMAN DR. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8: 967-974.
10. ZHANG Z, ZHENG M, BINDAS J, SCHWARZENBERGER P, KOLLS JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006; 12: 382-388.
11. YANG XO, CHANG SH, PARK H, NURIEVA R, SHAH B, ACERO L, WANG YH, SCHLUNS KS, BROADDUS RR, ZHU Z, DONG C. Regulation of inflammatory responses by IL-17F. J Exp Med 2008; 205: 1063-1075.
12. MOSELEY TA, HAUDENSCHILD DR, ROSE L, REDDI AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155-174.
13. AGGARWAL S, GHILARDI N, XIE MH, DE SAUVAGE FJ, GURNEY AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
14. LANGRISH CL, CHEN Y, BLUMENSCHEIN WM, MATTSON J, BASHAM B, SEDGWICK JD, MCCLANAHAN T, KASTELEIN RA, CUA DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 23-40.
15. OUYANG W, KOLLS JK, ZHENG Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467.
16. MUDTER J, NEURATH MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007; 13: 1016-1023.
17. ROSE-JOHN S, MITSUYAMA K, MATSUMOTO S, THAISS WM, SCHELLER J. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des 2009; 15: 2095-2103.
18. OKAYASU I, HATAKEYAMA S, NAKAYA R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
19. JUDITH H, ISABELL Y, HANS-WILLI H. IL-6 controls the innate immune response against listeria monocytogenes via classical IL-6 signaling. J Immunol 2013; 15: 703-711.